(Times of Israel) Luke Tress - Israeli immunotherapy company Enlivex Therapeutics said Wednesday that 16 severe and critical Covid-19 patients who received its experimental treatment had survived a 28-day Phase II clinical trial. 14 patients recovered and were discharged from the hospital an average of 5.3 days after receiving Allocetra. Allocetra treats the over-response of the immune system called a cytokine storm which attacks the body's own organs.
2021-02-04 00:00:00Full ArticleBACK Visit the Daily Alert Archive